N/A
N=312
Predicting Severe Toxicity of Targeted Therapies in Elderly Patients With Cancer
Cancer
Bottom Line
View on ClinicalTrials.gov: NCT02751827 ↗Enrolled (actual)
312
Serious AEs
42.4%
Results posted
Jun 2021
Primary outcome: Primary: Rate of Severe Toxicity — 14; 75; 43 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Blood sample (Other)
- Age
- Older Adult · 70+ yrs
- Sex
- All
- Sponsor
- Institut Bergonié
- Primary completion
- Nov 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Rate of Severe Toxicity |
14; 75; 43 | — |
Summary
In order to assess the important issue of the safety of antiangiogenic TKI in geriatric population we set up this project which aims to identify, among clinical, biological, pharmacokinetic data, predictive factors for severe toxicity of antiangiogenic TKI (sunitinib, sorafenib, pazopanib, regorafenib, axitinib) in patients over 70 year-old.
Eligibility Criteria
Inclusion Criteria
- Age ≥ 70 years
- Treatment with pazopanib, regorafenib, sorafenib, sunitinib,axitinib in the context of market authorization
- Voluntary signed and dated written informed consent prior to any study specific procedure.
Exclusion Criteria
- Patient treated in a context of clinical trial
- Patient with altered mental status or psychiatric disorder that, in the opinion of the investigator, would preclude a valid patient consent
Data sourced from ClinicalTrials.gov (NCT02751827). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.